MedTrace Logo

Clinical Study of the Sonablate® 500 to Treat Localized (T1c/T2a) Prostate Cancer

NCT00770822 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 466

Last updated 2019-04-10

No results posted yet for this study

Summary

This study will compare high intensity focused ultrasound to standard brachytherapy in the treatment of primary, organ confined prostate cancer.

Conditions

Interventions

DEVICE

HIFU (Sonablate® 500)

High Intensity Focused Ultrasound

DEVICE

Brachytherapy

Standard of care

Sponsors & Collaborators

  • SonaCare Medical

    lead INDUSTRY

Principal Investigators

  • Mark Schoenberg, M.D. · Johns Hopkins Medical Institution

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-30
Primary Completion
2020-07-31
Completion
2020-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00770822 on ClinicalTrials.gov